- Home
- PTIX vs REVB Comparison
PTIX vs REVB Comparison
Compare PTIX & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- REVB
- Stock Information
- Founded
- PTIX 1994
- REVB 2020
- Country
- PTIX United States
- REVB United States
- Employees
- PTIX N/A
- REVB N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- PTIX Health Care
- REVB Health Care
- Exchange
- PTIX Nasdaq
- REVB Nasdaq
- Market Cap
- PTIX 2.0M
- REVB 2.3M
- IPO Year
- PTIX 2016
- REVB N/A
- Fundamental
- Price
- PTIX $0.27
- REVB $4.31
- Analyst Decision
- PTIX
- REVB
- Analyst Count
- PTIX 0
- REVB 0
- Target Price
- PTIX N/A
- REVB N/A
- AVG Volume (30 Days)
- PTIX 599.7K
- REVB 175.9K
- Earning Date
- PTIX 03-31-2025
- REVB 03-21-2025
- Dividend Yield
- PTIX N/A
- REVB N/A
- EPS Growth
- PTIX N/A
- REVB N/A
- EPS
- PTIX N/A
- REVB N/A
- Revenue
- PTIX N/A
- REVB N/A
- Revenue This Year
- PTIX N/A
- REVB N/A
- Revenue Next Year
- PTIX N/A
- REVB N/A
- P/E Ratio
- PTIX N/A
- REVB N/A
- Revenue Growth
- PTIX N/A
- REVB N/A
- 52 Week Low
- PTIX $0.25
- REVB $3.34
- 52 Week High
- PTIX $1.87
- REVB $69.44
- Technical
- Relative Strength Index (RSI)
- PTIX 34.94
- REVB 40.86
- Support Level
- PTIX $0.25
- REVB $3.80
- Resistance Level
- PTIX $0.30
- REVB $4.54
- Average True Range (ATR)
- PTIX 0.03
- REVB 0.37
- MACD
- PTIX 0.00
- REVB 0.18
- Stochastic Oscillator
- PTIX 10.43
- REVB 68.13
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).